atropine has been researched along with rofecoxib in 9 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (rofecoxib) | Trials (rofecoxib) | Recent Studies (post-2010) (rofecoxib) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 1,914 | 307 | 163 |
| Protein | Taxonomy | atropine (IC50) | rofecoxib (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.43 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 1.51 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.5 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.5 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.02 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.8 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3602 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.76 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.486 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.036 | |
| Sodium-dependent serotonin transporter | Macaca mulatta (Rhesus monkey) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bohlin, L; Huss, U; Perera, P; Ringbom, T; Vasänge, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Hayashi, Y; Kubo, Y; Takeuchi, K; Tanaka, A | 1 |
| Takahira, Y; Takeuchi, K; Tanaka, A; Taniguchi, M; Yokota, A | 1 |
| Takeuchi, K; Tanaka, A; Taniguchi, M; Yokota, A | 1 |
9 other study(ies) available for atropine and rofecoxib
| Article | Year |
|---|---|
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
Topics: Acrolein; Alkaloids; Animals; Anthraquinones; Aspirin; Biological Assay; Catalysis; Cinnamomum zeylanicum; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Eugenol; Flavonoids; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Kinetics; Lactones; Models, Molecular; Nitrobenzenes; Oleanolic Acid; Plants, Medicinal; Prostaglandin-Endoperoxide Synthases; Pyrogallol; Steroids; Sulfonamides; Sulfones; Syzygium; Terpenes; Triterpenes; Ursolic Acid | 2002 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Functional mechanism underlying COX-2 expression following administration of indomethacin in rat stomachs: importance of gastric hypermotility.
Topics: Animals; Atropine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastrointestinal Motility; Indomethacin; Isoenzymes; Lactones; Male; Omeprazole; Peroxidase; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Stomach; Stomach Ulcer; Sulfones | 2004 |
Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atropine; Colony Count, Microbial; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Enterobacteriaceae; Gastric Mucosa; Gastrointestinal Motility; Indomethacin; Intestinal Diseases; Intestinal Mucosa; Lactones; Male; Membrane Proteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Ulcer; Sulfones | 2005 |
Development of intestinal, but not gastric damage caused by a low dose of indomethacin in the presence of rofecoxib.
Topics: Ampicillin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atropine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Gastric Mucosa; Gastrointestinal Motility; Gene Expression; Guanidines; Indomethacin; Intestinal Mucosa; Intestine, Small; Lactones; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Stomach; Sulfones | 2005 |